Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Revenue (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Revenue readings, the most recent being $199.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Revenue fell 5.94% year-over-year to $199.9 million, compared with a TTM value of $1.0 billion through Dec 2025, up 28.46%, and an annual FY2025 reading of $1.0 billion, up 28.46% over the prior year.
  • Revenue hit $199.9 million in Q4 2025 for Apellis Pharmaceuticals, down from $458.6 million in the prior quarter.
  • The five-year high for Revenue was $458.6 million in Q3 2025, with the low at $623000.0 in Q2 2021.
  • Median Revenue over the past 5 years was $110.4 million (2023), compared with a mean of $122.3 million.
  • The sharpest move saw Revenue crashed 75.88% in 2021, then skyrocketed 2519.9% in 2022.
  • Year by year, Revenue stood at $60.3 million in 2021, then tumbled by 62.41% to $22.7 million in 2022, then soared by 545.89% to $146.4 million in 2023, then soared by 45.19% to $212.5 million in 2024, then fell by 5.94% to $199.9 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $199.9 million, $458.6 million, and $178.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.